1 / 42

The Global Epidemics of HIV among MSM in 2010 Epidemiology, Responses, and Human Rights Results of a Project Supported

The Global Epidemics of HIV among MSM in 2010 Epidemiology, Responses, and Human Rights Results of a Project Supported by the World Bank. Stefan Baral MD MPH FRCPC Johns Hopkins School of Public Health, USA . Overview. Introduction Know your epidemic Epidemiology of HIV among MSM

brendy
Télécharger la présentation

The Global Epidemics of HIV among MSM in 2010 Epidemiology, Responses, and Human Rights Results of a Project Supported

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Global Epidemics of HIV among MSM in 2010Epidemiology, Responses, and Human RightsResults of a Project Supported by the World Bank Stefan Baral MD MPH FRCPC Johns Hopkins School of Public Health, USA

  2. Overview • Introduction • Know your epidemic • Epidemiology of HIV among MSM • Epidemic Scenarios of HIV among MSM • Burden of Disease • Risk Factors for Disease • Know your Response • Combination HIV Prevention Interventions for MSM • Using GOALS Model to Predict HIV Epidemics with varying levels of coverage of preventive services for MSM • The role of Human Rights in Responding to HIV • Conclusions

  3. Introduction • Epidemiology • Ongoing epidemics among MSM in multiple LMIC • Newly identified epidemics in previously unstudied areas • Resurgent epidemics among MSM in high income countries (HIC) • Responses • Inadequate coverage and access for prevention, treatment, and care • Inadequate “toolkit” of prevention services for MSM • Human Rights: • Multiple advances in LGBT rights awareness, community empowerment, activism • Major “pushback” on MSM/LGBT and rights effort

  4. Epidemiology Potentially relevant studies identified and abstracts screened for retrieval from international conference searches (n=819) Potentially relevant studies identified and abstracts screened for retrieval from literature Searches (n=1612) Duplicates Studies excluded (n=255) Reports excluded based on abstract due to lack of quantitative data, geographical context, sample size, self-reported HIV status. (n=1434) Abstracts excluded based on abstract due to lack of quantitative data, geographical context, sample size, self-reported HIV status. (n=503) Full texts retrieved for further analysis with QUOSA (n=178) Conference abstracts retrieved for further analysis (n=61) Reports excluded based on lack of HIV prevalence data, inability to calculate country population HIV prevalence (n=111) Abstracts excluded based on inability to find background data on specific country HIV prevalence, inability to find further information on statistical methods (n=8) Studies retrieved that were coordinated by EuroHIV and commissioned by European Union (n=16) Unique studies retrieved from US Census Bureau Database for HIV/AIDS (n=2) 133 prevalence studies from 130 unique reports: data from 50 countries --Beyrer, et al, Epi Reviews, 2010

  5. Epidemic Scenarios for MSM • Evidence suggested four epidemic scenarios for LMIC MSM epidemics • Scenario 5 will come from MENA region: now largely “unavailable data” Beyrer C, et al, Epidemiology Reviews, 2010.

  6. Scenario 1 - MSM risks are the predominant exposure mode for HIV infection in the population 

  7. SCENARIO1MSM are the predominant exposure group for HIV Beyrer C, et al, Epidemiology Reviews, 2010.

  8. Scenario 2- MSM risks occur within established HIV epidemics driven by injecting drug use (IDU)

  9. SCENARIO 2: Same sex behavior is evaluated in the context of established HIV epidemics among IDU Beyrer C, et al, Epidemiology Reviews, 2010.

  10. Scenario 3 - MSM risks occur in the context of mature and widespread HIV epidemics among heterosexuals

  11. SCENARIO 3: Same sex behavior is evaluated in the context of high prevalence and mature HIV epidemics among heterosexuals Beyrer C, et al, Epidemiology Reviews, 2010.

  12. SCENARIO 4: MSM, heterosexual, and IDU transmission all contribute significantly to the HIV epidemic

  13. SCENARIO 4: MSM, heterosexual, and IDU transmission all contribute significantly to the HIV epidemic Beyrer C, et al, Epidemiology Reviews, 2010.

  14. EPIDEMIC SCENARIOS: Unavailable Data • Algeria • Azerbaijan • Belarus • Djibouti • Iran • Iraq • Jordan • Kazakhstan • 130 other Countries • Kyrgyzstan • Lebanon • Libya • Morocco • Syria • Tunisia • West Bank and Gaza

  15. Assessment of Data Quality • Disease burden among MSM in LMIC • Nearly all data is prevalence data from convenience samples • Tells us where epidemic was and not where it is going • May not be generalizable to general population of MSM • Samples are among young MSM—so likely very conservative estimates of disease burden • HIV Incidence has been characterized in cohort studies in Kenya, Peru, Brazil

  16. Individual Risk factors for MSM • Unprotected anal intercourse ( risk with receptive UAI) • High frequency of male partners (>3 sexual contacts/ week) • High number of lifetime male partners (>10) • Injection drug use • Alkyl Nitrate (poppers) • Methamphetamines • Lack of Circumcision (for predominantly insertive MSM with female partners) Mediated through increased sexual exposure Beyrer, C. STD, 2007

  17. Level of Risks Stage of Epidemic Public Policy Community Network Individual Ecological Model for HIV Risk in MSM HIV Epidemic Stage Exclusion from National Surveillance, Criminalization, Human Rights Contexts, Condom Availability, Sexual Health Education Access to preventive services, Stigma, VCT Access, ARV Access STI Prevalence, Condom knowledge, IDUs, MSW, Transgenders Unprotected Receptive Anal Intercourse, GUD, Lack of circumcision, frequency of male partners, high lifetime partners, IDU, poppers, meth Source: Baral and Beyrer, 2006

  18. HIV among MSM in High Income Countries Source: Sullivan, et al, 2009. Reemergence of the HIV Epidemic Among Men Who Have Sex With Men in North America, Western Europe, and Australia, 1996–2005

  19. Number of newly diagnosed HIV infections among men who have sex with men, Hong Kong, Singapore, Taiwan and Japan, 2002 - 2007 TaiwanJapan Hong KongSingapore HK 56 50 67 96 118 168 SG 38 54 94 101 108 145 TW - 336 503 584 743 1075 JP 305 340 449 514 571 690 Source: van Griensven, Baral, et al. 2009. The Global Epidemic of HIV Infection among Men who have Sex with Men. Current Opinion in HIV/AIDS

  20. Know Your Response • There is a dearth of data characterizing effective HIV prevention interventions for MSM in Low and Middle Income Countries • Systematic review completed of HIV prevention data for MSM in Low and Middle Income Countries as well as Global Consultation of Community Best Practices • Data was evaluated to assess current state of evidence for interventions to assess benefit • To respond to multiple levels of HIV risk among MSM, combination prevention must be multi-level and multimodal

  21. A modified Grade approach for HIV preventive interventions • Grading Evidence • 3 Primary Parameters • Efficacy Data • Biological Plausibility • Community Best Practices • 6 Grades • Strong • Probable • Possible • Pending • Insufficient • Inappropriate

  22. Combination HIV Prevention Interventions for MSM (CHPI) • CHPI Includes • Behavioural Interventions • Increasing condom and lubricant use during sex • Biomedical Interventions • Biomedical interventions aim to decrease transmission and acquisition risk of but don’t decrease prevalence of risk practices • Structural Interventions • These have rarely been appropriately evaluated likely because of complexity in study design to characterize efficacy and effectiveness of these interventions

  23. Prevention Expenditures for MSM • Concentrated Epidemics • MSM are one of predominant risk groups (Epidemic Scenario 1, 2, 4) • 3.3% of total expenditures supporting MSM • Generalized Epidemics (Epidemic Scenario 3) • Emerging evidence of risk among MSM • 0.1% of total expenditures supporting MSM Source: Global HIV Prevention Working Group: Global HIV Prevention: The Access, Funding, and Leadership Gaps. 2009

  24. Prevention Expenditures - Asia Source: USAID, HIV Expenditure on MSM Programming in the Asia-Pacific Region., 2006

  25. Prevention Expenditures – Latin America Peru Source: Medición del gasto en sida: avances y retos de la respuesta latinoamericana al VIH. ONUSIDA. 2010

  26. Predicting impact of interventions on incidence and prevalence levels • Estimates the number of ALL new HIV infections with and without interventions for 4 different epidemic scenarios: Peru, Ukraine, Kenya, Thailand • Null: both MSM interventions and ARV for general population dropped from 2007 levels to zero • Current: most recent coverage levels of MSM interventions and ARVs continue at same level to 2015 • 100% coverage of MSM: MSM interventions incrementally increase from last reported level to 100% by 2015, ARVs increase to estimated level in which all MSM would be covered • For epidemics with IDU components (Scenarios 2 and 4), modeled combined impact of 100% coverage of MSM and 60% coverage of IDU

  27. Using the Goals Model • Goals is a deterministic model that uses data to project HIV prevalence and incidence: uses demography; sexual behavior; HIV and STI rates • We have refined the model by including • Separated “MSM intervention” to separate parameters • Expanded risk categorization for MSM to low, medium, and high risk, and MSM IDU • High Risk: Male sex workers • Medium Risk:> 1 male sex partner in last 12 months • Low Risk: 0 – 1 male sex partner in last 12 months (stable relationship) • MSM IDU: Men who report same sex practices and inject drugs Source: Bollinger, L. How can we calculate the ‘‘E’’ in ‘‘CEA’’? AIDS 2008, Futures Institute

  28. Scenario 1: Impact of MSM interventions on all new HIV infections in Peru Null Current 100% MSM interventions

  29. Peru • Modeling outcomes: combined prevention for MSM • Markedly higher coverage of interventions for MSM will be necessary to change trajectory of HIV epidemic in Peru

  30. Scenario 2: Impact of MSM interventions on all new HIV infections in Ukraine Null Current 100% MSM interventions

  31. Scenario 2: Impact of MSM and IDU interventions on all new HIV infections in Ukraine Null Current 100% MSM interventions 100% MSM + 60% IDU

  32. Ukraine • Modeling outcomes: combined prevention for MSM • Higher coverage of interventions for MSM has impact on the HIV epidemic in Ukraine • Combinations with IDU interventions have the greatest impact on the HIV epidemic

  33. Scenario 3: Impact of MSM interventions on all new HIV infections in Kenya Null Current 100% MSM interventions

  34. Scenario 3: Impact of MSM interventions on all new HIV infections in Kenya Null Current 100% MSM interventions

  35. Kenya • Modeling outcomes: combined prevention for MSM • Even where the HIV prevalence is high and mature among the heterosexual population, MSM specific interventions positively impact the general population

  36. Scenario 4: Impact of MSM interventions on all new HIV infections in Thailand Null Current 100% MSM interventions

  37. Scenario 4: Impact of MSM and IDU interventions on all new HIV infections in Thailand Null Current 100% MSM interventions 100% MSM + 60% IDU

  38. Thailand • Modeling outcomes: combined prevention for MSM • Thai epidemic is stable overall • Higher levels of coverage for MSM with existing interventions would lead to overall declines in HIV epidemic • Substantial increases in coverage of IDU interventions have major impact on the HIV epidemic

  39. Modeling the impact of MSM interventions and ARVsKey messages • MSM specific interventions (community-based behavioral and distribution of condoms and lubricants) impact new infections among MSM and general population but must include access to ARVs for MSM • Benefits may be seen even in varying epidemic scenarios • Where IDU plays a role in the epidemic, the greatest impact among the general population can be seen when coverage of needle exchange and substitution therapy are increased as well

  40. Human Rights Contexts • Methods • Health Impact Assessment of criminalization of same-sex practices as a risk factor for HIV among MSM • Participatory methods in selected case study countries including Malawi, Uganda, and Senegal • Results • Increased enforcement of laws criminalizing same sex practices have resulted in widespread fear and hiding and interfered with the ability to provide HIV prevention, care, and treatment services • These arrests have also interfered with the ability of MSM to seek evidence-based HIV services resulting in increased HIV risk

  41. Conclusions • HIV continues to disproportionately affect MSM in high and low income settings • There are both Individual and Structural risk factors for HIV infection • To improve the health outcomes of MSM in low and middle income settings, a comprehensive effort is needed: • Know your Epidemic by • Generating high quality epidemiologic data to • characterize populations • demonstrate need • inform prevention strategies • Know your Response by • Adopting comprehensive prevention strategies that address multiple levels of risk • Appropriately resourcing prevention programs for MSM in response to attributable fraction of HIV disease

  42. Acknowledgements Know your Epidemic and Response Session Team • Shiv Khan, OBE • Zoryan Kis • Andy Seale • Rob Carr • Joel Nana • Nyambura Njoroge • Maria Prins, Allison Talan Center for Public Health and Human Rights, Johns Hopkins Chris Beyrer MD, MPH Frangiscos Sifakis, PhD, MPH Andrea Wirtz, MHS Damian Walker, PhD Benjamin Johns, MHA The Futures Institute John Stover, PhD Lori Bollinger, PhD Global HIV/AIDS ProgramThe World Bank Robert Oelrichs, MD, PhD, MPH Iris Semini, PhD Laith Abu-Raddad, PhD David Wilson, PhD

More Related